Overview of the Medicare prescription drug subsidy program

This policy was initiated after the 2022 Inflation Reduction Act (IRA) revised Medicare Part D mechanisms, especially imposing annual self-pay caps at $2,000 in 2025 and $2,100 in 2026, increasing annually. Previously, patients using specialty drugs for cancer or rheumatoid arthritis could have incurred costs up to tens of thousands of dollars.

Causes and effectiveness of the subsidy program

Although the IRA limited self-pay costs, it did not lower drug prices but shifted major costs to insurance companies managing Medicare Part D programs. Without pricing experience under the new mechanism, insurers sharply increased insurance premiums, especially for standalone prescription drug plans.

To mitigate the impact of sudden premium increases, the Biden administration launched a pilot program in 2024, applicable to the 2025 planning year. This program reduced the national standard premium rate and limited monthly premium increases for each insurance plan. In 2025, the base premium decreased by 15 USD and the maximum premium increase was 35 USD/month. In 2026, under the Trump administration, the reduction was 10 USD and the maximum premium increase was 50 USD, while cutting back some risk mitigation measures for insurers.

According to estimates from the Medicare Payment Advisory Commission (MedPAC), the program helped reduce average individual premium costs by 26 USD in 2025 and 16 USD in 2026. Although many experts predicted a sharp decline in enrollment, the number of people signing up for these plans actually increased from 22.8 million in 2024 to 24.9 million in 2026. However, the program also caused the U.S. government to spend nearly 10 billion USD over two years.